Advertisement

Outcomes and efficacy of thoracic surgery biopsy for tumor molecular profiling in patients with advanced lung cancer

      Background

      Molecular testing of patients with advanced non–small cell lung cancer for personalized therapy often is limited by insufficient specimen from nonsurgical biopsies. We measured the feasibility, patient safety, and clinical impact of thoracic surgical tumor biopsy in patients with stage IV non–small cell lung cancer.

      Methods

      This is a single institution retrospective analysis. Patients with stage IV non–small cell lung cancer undergoing elective surgical tissue biopsy for molecular analysis were evaluated from March 2011 to November 2012. Perioperative specific variables were measured.

      Results

      Twenty-five patients with known or suspected stage IV non–small cell lung cancer undergoing surgical biopsy were identified. All cases were discussed at a multidisciplinary thoracic oncology conference or a multidisciplinary thoracic oncology clinic. Preoperative histologies included adenocarcinoma in 20 patients (80.0%) and squamous cell carcinoma in 2 patients (8.0%). Surgical procedures consisted of video-assisted thoracic surgery wedge biopsy (16, 64%), video-assisted thoracic surgery pleural biopsy (4, 16.0%), mediastinoscopy (2, 8.0%), supraclavicular/cervical lymph node excisional biopsy (3, 12.0%), and rib/chest wall resection (2, 8.0%). There were no deaths and 5 postoperative complications (20.0%). Surgery identified potentially targetable molecular information in 19 of the total patients undergoing operation (76.0%) and changed the treatment strategy in 14 patients (56.0%); 10 of the total cohort (40.0%) were enrolled into therapeutic targeted clinical trials.

      Conclusions

      These data suggest that thoracic surgical biopsy can be safely performed in appropriately selected patients with stage IV non–small cell lung cancer and direct personalized therapy and enrollment into relevant clinical trials. Patients with advanced-stage non–small cell lung cancer should be discussed in a multidisciplinary setting to determine the need and strategy for thoracic surgical biopsy for molecular analysis.

      CTSNet classification

      Abbreviations and Acronyms:

      CI (confidence interval), CT (computed tomography), EGFR (epidermal growth factor receptor), EML4-ALK (echinoderm microtubule-associated protein-like 4 and anaplastic lymphoma kinase), NSCLC (non–small cell lung cancer), PLOS (prolonged length of stay), RRM1 (ribonucleoside-diphosphate reductase large subunit), TKI (tyrosine kinase inhibitor)
      To read this article in full you will need to make a payment

      References

        • Schrump D.S.
        • Giaccone G.
        • Kelsey C.R.
        • Marks L.B.
        Non-small cell lung cancer.
        in: DeVita V.T. Lawrence T.S. Rosenberg S.A. DeVita, Hellman, and Rosenberg's Cancer: Principles and Practices of Oncology. Lippincott Williams and Wilkins, Philadelphia2008: 896-945
        • Villaruz L.C.
        • Socinski M.A.
        Personalized therapy for non-small cell lung cancer: which drug for which patient?.
        Semin Thorac Cardiovasc Surg. 2011; 23: 281-290
        • Kwak E.L.
        • Bang Y.J.
        • Camidge D.R.
        • Shaw A.T.
        • Solomon B.
        • Maki R.G.
        • et al.
        Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
        N Engl J Med. 2010; 363: 1693-1703
        • Olaussen K.A.
        • Dunant A.
        • Fouret P.
        • Brambilla E.
        • André F.
        • Haddad V.
        • et al.
        • IALT Bio Investigators
        DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.
        N Engl J Med. 2006; 355: 983-991
        • Lindeman N.I.
        • Cagle P.T.
        • Beasley M.B.
        • Chitale D.A.
        • Dacic S.
        • Giaccone G.
        • et al.
        Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.
        J Thorac Oncol. 2013; 8: 823-859
        • Reck M.
        • Hermes A.
        • Tan E.H.
        • Felip E.
        • Klughammer B.
        • Baselga J.
        Tissue sampling in lung cancer: a review in light of the MERIT experience.
        Lung Cancer. 2011; 74: 1-6
        • Coghlin C.L.
        • Smith L.J.
        • Bakar S.
        • Stewart K.N.
        • Devereux G.S.
        • Nicolson M.C.
        • et al.
        Quantitative analysis of tumor in bronchial biopsy specimens.
        J Thorac Oncol. 2010; 5: 448-452
        • Cheung Y.C.
        • Chang J.W.
        • Hsieh J.J.
        • Lin G.
        • Tsai Y.H.
        Adequacy and complications of computed tomography-guided core needle biopsy on non-small cell lung cancers for epidermal growth factor receptor mutations demonstration: 18-gauge or 20-gauge biopsy needle.
        Lung Cancer. 2010; 67: 166-169
        • Blackhall V.
        • Asif M.
        • Renieri A.
        • Civitelli S.
        • Kirk A.
        • Jilaihawi A.
        • et al.
        The role of surgical lung biopsy in the management of interstitial lung disease: experience from a single institution in the UK.
        Interact Cardiovasc Thorac Surg. 2013; 17: 253-257
        • Lettieri C.J.
        • Veerappan G.R.
        • Helman D.L.
        • Mulligan C.R.
        • Shorr A.F.
        Outcomes and safety of surgical lung biopsy for interstitial lung disease.
        Chest. 2005; 127: 1600-1605
        • Wright C.D.
        • Gaissert H.A.
        • Grab J.D.
        • O'Brien S.M.
        • Peterson E.D.
        • Allen M.S.
        Predictors of prolonged length of stay after lobectomy for lung cancer: a Society of Thoracic Surgeons General Thoracic Surgery Database risk-adjustment model.
        Ann Thorac Surg. 2008; 85: 1857-1865
        • Farjah F.
        • Wood D.E.
        • Varghese T.K.
        • Massarweh N.N.
        • Symons R.G.
        • Flum D.R.
        Health care utilization among surgically treated Medicare beneficiaries with lung cancer.
        Ann Thorac Surg. 2009; 88: 1749-1756
        • Ohashi K.
        • Maruvka Y.E.
        • Michor F.
        • Pao W.
        Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.
        J Clin Oncol. 2013; 31: 1070-1080
        • Chow C.J.
        • Habermann E.B.
        • Abraham A.
        • Zhu Y.
        • Vickers S.M.
        • Rothenberger D.A.
        • et al.
        Does enrollment in cancer trials improve survival?.
        J Am Coll Surg. 2013; 216: 774-780
        • Shaw A.T.
        • Yeap B.Y.
        • Solomon B.J.
        • Riely G.J.
        • Gainor J.
        • Engelman J.A.
        • et al.
        Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
        Lancet Oncol. 2011; 12: 1004-1012
        • Maemondo M.
        • Inoue A.
        • Kobayashi K.
        • Sugawara S.
        • Oizumi S.
        • Isobe H.
        • et al.
        • North-East Japan Study Group
        Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
        N Engl J Med. 2010; 362: 2380-2388
        • Ettinger D.S.
        • Akerley W.
        • Borghaei H.
        • Chang A.C.
        • Cheney R.T.
        • Chirieac L.R.
        • et al.
        Non-small cell lung cancer, version 2.2013.
        J Natl Compr Canc Netw. 2013; 11: 645-653